Compare Stocks

→ Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EMH Emerald Health Therapeutics	C$0.26 -3.8%	C$0.26	C$0.15 ▼ C$0.53	C$52.28M	N/A	644,760 shs	384,329 shs
FAB First Trust Multi Cap Value AlphaDEX Fund	$78.78 -1.1%	$79.23	$64.89 ▼ $82.62	$153.62M	1.22	5,459 shs	957 shs
IGX IntelGenx Technologies	C$0.58 +1.8%	C$0.58	C$0.17 ▼ C$0.85	C$87.32M	N/A	56,279 shs	11,848 shs
RENE Cartesian Growth Co. II	$11.20	$11.11	$10.52 ▼ $11.92	$242.14M	-0.01	57,464 shs	1,160 shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EMH Emerald Health Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
FAB First Trust Multi Cap Value AlphaDEX Fund	-0.01%	+3.04%	-1.04%	+3.70%	+17.94%
IGX IntelGenx Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
RENE Cartesian Growth Co. II	0.00%	+0.18%	+0.81%	+1.63%	+6.46%

The Hard Truth About Investing For Retirement (Ad)

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

Click To Access This Powerful Training Right Now!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EMH Emerald Health Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IGX IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EMH Emerald Health Therapeutics	N/A	N/A	N/A	N/A
FAB First Trust Multi Cap Value AlphaDEX Fund	0.00	N/A	$86.80	10.17% Upside
IGX IntelGenx Technologies	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EMH Emerald Health Therapeutics	C$13.02M	4.02	C$0.33 per share	0.78	C$0.40 per share	0.64
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A	N/A	N/A	N/A	N/A	N/A
IGX IntelGenx Technologies	C$1.75M	49.95	C$0.08 per share	7.16	C$0.05 per share	12.89
RENE Cartesian Growth Co. II	N/A	N/A	$0.40 per share	28.14	($0.64) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EMH Emerald Health Therapeutics	N/A	-C$0.70	N/A	∞	N/A	N/A	N/A	N/A	N/A
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A	N/A	11.74	∞	N/A	N/A	N/A	N/A	N/A
IGX IntelGenx Technologies	N/A	-C$0.08	N/A	∞	N/A	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	$11.44M	N/A	0.00	∞	N/A	N/A	-65.59%	5.02%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EMH Emerald Health Therapeutics	N/A	N/A	N/A	N/A	N/A
FAB First Trust Multi Cap Value AlphaDEX Fund	$1.48	1.88%	N/A	N/A	N/A
IGX IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A	N/A

Latest EMH, FAB, HVO, IGX, and RENE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/20/2024	FAB First Trust Multi Cap Value AlphaDEX Fund	Quarterly	$0.2430		3/21/2024	3/22/2024	3/28/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EMH Emerald Health Therapeutics	35.45	2.97	2.61
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A	N/A	N/A
IGX IntelGenx Technologies	164.62	2.77	2.69
RENE Cartesian Growth Co. II	N/A	0.22	0.22

Ownership

Institutional Ownership

Company	Institutional Ownership
EMH Emerald Health Therapeutics	N/A
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A
IGX IntelGenx Technologies	N/A
RENE Cartesian Growth Co. II	58.96%

Insider Ownership

Company	Insider Ownership
EMH Emerald Health Therapeutics	N/A
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A
IGX IntelGenx Technologies	N/A
RENE Cartesian Growth Co. II	20.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EMH Emerald Health Therapeutics	161	205.03 million	N/A	Not Optionable
FAB First Trust Multi Cap Value AlphaDEX Fund	147,000	1.95 million	N/A	Not Optionable
IGX IntelGenx Technologies	48	150.55 million	N/A	Not Optionable
RENE Cartesian Growth Co. II	N/A	21.62 million	17.30 million	Not Optionable

EMH, FAB, HVO, IGX, and RENE Headlines

Source	Headline
	Wolverine Asset Management LLC Acquires 104,768 Shares of Cartesian Growth Co. II (NASDAQ:RENE) marketbeat.com - April 23 at 8:48 PM
	Cartesian Growth Co. II (NASDAQ:RENE) Shares Up 0% americanbankingnews.com - April 19 at 2:58 AM
	Cartesian Growth Co. II (NASDAQ:RENE) Short Interest Update marketbeat.com - March 28 at 8:23 PM

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
Charles Schwab Fortifies its Uptrend on EPS Beat
April 23, 2024 10:15 AM
View Charles Schwab Fortifies its Uptrend on EPS Beat
Silicon Motion Proves That AI in Motion Stays in Motion
April 16, 2024 11:42 AM
View Silicon Motion Proves That AI in Motion Stays in Motion

All Headlines

Company Descriptions

Emerald Health Therapeutics

CVE:EMH

Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.

First Trust Multi Cap Value AlphaDEX Fund

NASDAQ:FAB

The First Trust Multi Cap Value AlphaDEX Fund (FAB) is an exchange-traded fund that is based on the NASDAQ AlphaDEX Multi Cap Value index. The fund tracks an index that uses fundamental factors to select and weight value stocks from the Nasdaq US Select Indices. FAB was launched on May 8, 2007 and is managed by First Trust.

IntelGenx Technologies

CVE:IGX

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Cartesian Growth Co. II

NASDAQ:RENE

Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. Cartesian Growth Corporation II was incorporated in 2021 and is based in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial